Regencell Bioscience's extraordinary 21,000% stock surge over the past year appears disconnected from fundamentals, with the pre-commercial biotech having minimal clinical progress and expressing doubt about its ability to remain in business. In contrast, Pfizer offers a more prudent investment with its robust pipeline including promising GLP-1 candidate MET-097i, cost-cutting improvements, attractive 8.7x forward earnings valuation, and a solid 6.4% dividend yield.

The author explains why he avoids investing in Teva Pharmaceutical despite recognizing its opportunities. While Teva's traditional generic drug business is lucrative, increased competition has eroded profits. The company's pivot toward complex generics and original drug development introduces higher risk in a highly competitive sector. The author cites concerns about Teva's ability to pivot if its drug pipeline underperforms, contrasting it with larger competitors like Pfizer that have greater resources to adapt.

Fight Colorectal Cancer launches its fifth annual United in Blue installation on the National Mall from March 1-14, 2026, featuring over 27,000 blue flags representing people under 50 projected to be diagnosed with colorectal cancer in 2030. The installation comes as new American Cancer Society research confirms colorectal cancer has become the deadliest cancer for Americans under 50, with mortality increasing in 2025.

Ahead of the March 6, 2026 FDA decision on Bristol Myers Squibb's Sotyktu (deucravacitinib) for psoriatic arthritis, a survey of 104 U.S. rheumatologists shows strong pre-launch awareness with one-third viewing it as a substantial advance. However, BMS ranks lowest among major pharmaceutical partners in rheumatology and is expected to capture roughly one-fifth of PsA patients through brand-to-brand share shifts rather than market expansion. The launch represents a critical opportunity for BMS to strengthen its standing in the specialty.

PatentVest released an analysis of 1,200+ patent documents across 50 oral small-molecule GLP-1 programs, revealing dramatic disparities in patent defensibility among competitors. With injectable GLP-1s reaching only 5% of eligible patients and clinical efficacy converging around 12-16% weight loss, long-term market dominance will depend on patent portfolio strength rather than clinical performance alone. Major patent cliffs for semaglutide (2031) and tirzepatide (2036) will determine which assets become franchises versus facing generic competition.

Juvenescence Limited announced successful completion of Phase 1 clinical trial for its PAI-1 inhibitor (MDI-2517), demonstrating good safety and tolerability with a once-daily dosing profile. The company strengthened its clinical development team with three key appointments: Carmel Nanthakumar as VP of Translational Biology, Paul Russell as Chief Development Officer, and Catherine McClinton as Head of Clinical Operations. A Phase 2 proof-of-concept trial is planned for later in 2026 in patients with metabolic and fibrotic diseases.

Eli Lilly strengthened its leading position in the GLP-1 weight loss drug market with two major developments: Novo Nordisk's CagriSema failed to outperform Lilly's Zepbound in clinical trials, and Lilly launched a new convenient monthly-dose pen format for Zepbound. With 60% U.S. market share and a projected $100 billion market over four years, Lilly is well-positioned for continued growth, though competition from Pfizer and Viking Therapeutics remains a potential threat.

The FDA granted full approval to Pfizer's Braftovi (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for treating metastatic colorectal cancer with BRAF V600E mutation. The approval is based on Phase 3 BREAKWATER trial results showing significant improvements in progression-free and overall survival. The regimen is also under regulatory review in Europe and has received approvals in other countries.

The global Advanced Drug Delivery Systems market is projected to grow from $299.6 billion in 2025 to $487.4 billion by 2030 at a CAGR of 10.2%. Growth is driven by increasing chronic disease prevalence, nanotechnology advances, and R&D investments. Oncology leads adoption, with North America dominating market share while Asia-Pacific shows the fastest growth. Key innovations include strategic partnerships in antibody-drug conjugates and AI-powered drug development optimization.

The global ophthalmic drugs market is projected to reach US$41.88 billion in 2026 and grow at 7.9% CAGR through 2036, driven by biologic innovation, anti-VEGF therapies, AI-enabled diagnostics, and long-acting drug delivery systems. Key developments include expanded digital distribution channels and sustained-release implants reducing treatment burden for retinal disorders.

Pfizer offers an attractive 6.4% dividend yield, significantly higher than the pharma sector average of 1.7%, making it appealing for income-focused investors. However, the company faces headwinds including patent expirations on key drugs and setbacks in new drug development. Despite a payout ratio above 100%, management has committed to supporting the dividend. The article suggests Pfizer's challenges are typical for the sector and the company is taking steps to address them through acquisitions and partnerships.

BioNTech has filed a patent infringement lawsuit against Moderna, alleging that Moderna's next-generation COVID-19 vaccine mNEXSPIKE infringes on BioNTech's patented domain-based spike protein technology. BioNTech claims the technology targets specific domains of the spike protein rather than the full structure, enabling lower doses and improved storage stability. Moderna has not sought licensing rights or provided compensation, according to BioNTech. The lawsuit seeks monetary damages as Moderna's COVID-19 vaccine sales reached $1.168 billion through Q3 2025.